Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment
| dc.contributor.author | Petersen, Ronald C. | |
| dc.contributor.author | Thomas, Ronald G. | |
| dc.contributor.author | Kaye, Jeffrey | |
| dc.contributor.author | Sano, Mary | |
| dc.date.accessioned | 2024-12-15T19:23:41Z | |
| dc.date.available | 2024-12-15T19:23:41Z | |
| dc.date.issued | 2005-04-13 | |
| dc.description.abstract | Mild cognitive impairment is a transitional state between the cognitive changes of normal aging and early Alzheimer’s disease. In a double-blind study, we evaluated subjects with the amnestic subtype of mild cognitive impairment. Subjects were randomly assigned to receive 2000 IU of vitamin E daily, 10 mg of donepezil daily, or placebo for three years. The primary outcome was clinically possible or probable Alzheimer’s disease; secondary outcomes were cognition and function. | |
| dc.identifier.citation | Petersen, R. C., Thomas, R. G., Grundman, M., Bennett, D., Doody, R., Ferris, S., ... & Thal, L. J. (2005). Vitamin E and donepezil for the treatment of mild cognitive impairment. New England Journal of Medicine, 352(23), 2379-2388. | |
| dc.identifier.other | vol. 352 no. 23 | |
| dc.identifier.uri | https://nru.uncst.go.ug/handle/123456789/9723 | |
| dc.language.iso | en | |
| dc.publisher | New England Journal of Medicine | |
| dc.title | Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment |